Biotech Valuation Platform for Asset, Portfolio, and Board Decisions
ARiDA runs evidence-backed biotech valuation workflows across single assets, multi-asset portfolios, platforms, fundraises, real options, Monte Carlo risk, and board dossiers.
Decision questions
What this solution is built to answer.
What is the defensible value range for this asset or portfolio?
Which assumptions move value most: probability of success, launch timing, price, peak share, discount rate, or loss of exclusivity?
How should single-asset value roll up into portfolio value with correlation and downside risk?
Does a platform deserve value beyond the visible program layer?
What should go into the board pack, investor memo, or fundraise negotiation model?
Capabilities
What ARiDA can run for this use case.
Single-asset risk-adjusted valuation with stage costs, probability of success, discounting, scenario samples, waterfalls, tornadoes, and value distributions.
Portfolio valuation with asset weights, correlations, diversification effects, and portfolio-level downside views.
Commercial modeling with geography, pricing corridors, penetration curves, reimbursement lag, loss-of-exclusivity erosion, and cash-flow stacks.
Platform valuation with visible program value plus platform option value from throughput, reuse, probability uplift, cycle time, and BD evidence.
Fundraise pricing with VC haircuts, cap-table dilution waterfalls, liquidation preference variants, and investor-thesis playbooks.
Workflow table
Named workflows and expected artifacts.
| Workflow | Role | Artifacts |
|---|---|---|
| valuation-essential-workflow | Single-asset valuation foundation | VALUATION__RNPV, S0, SENSITIVITY, WATERFALL, TORNADO, MEMO |
| valuation-professional-workflow | Multi-asset portfolio valuation | Portfolio value, scenarios, correlations, regional analysis, professional report |
| valuation-enterprise-workflow | Board-grade enterprise valuation | Real-options outputs, probability updates, platform diagnostics, optimization, board deck |
| valuation-fundraise-workflow | Fundraise and cap-table valuation | Pricing bands, cap-table simulation, term-sheet sensitivity, fundraise playbook |
Evidence inputs
Data sources, tools, and user context.
Outputs
What the workflow should leave behind.
Deliverables
Investor-grade valuation memo with assumption provenance and confidence labels.
Portfolio value files plus charts for waterfall, tornado, scenario, correlation, and downside risk.
Board-grade enterprise dossier and companion board deck for strategic decisions.
Fundraise pricing and dilution playbook with explicit negotiation ranges.
Proof points
Valuation work uses dedicated calculators, scenario steps, and visual outputs rather than generic chat prompts.
Monte Carlo outputs can persist as data files and plots for preview, download, and later review.
Enterprise valuation keeps per-asset, portfolio, platform, real-options, BD, risk, and board-pack phases in one workflow.
FAQ
Common evaluation questions.
Does ARiDA only calculate rNPV?
rNPV is the baseline. The valuation workflows also cover portfolio value, real-options analysis, platform value, probability updates, fundraise pricing, BD deal simulation, Monte Carlo risk, and board-ready reporting.
Can users override assumptions?
Yes. User-provided probabilities, costs, timelines, commercial assumptions, platform evidence, discount rates, and scenario definitions can override defaults. The workflow records provenance for each major assumption.
Related solutions
Advanced Valuation
Defend probability of success and valuation assumptions by tracing target biology, comparator trials, biomarkers, patents, sponsor history, market context, and evidence strength.
Real Options Analysis
Quantify the value of strategic flexibility in biotech R&D with binomial lattices, Longstaff-Schwartz Monte Carlo, compound options, Greeks, exercise boundaries, and option-value decomposition.
Portfolio Optimization
Prioritize and defend a biopharma portfolio with value modeling, correlation, downside risk, stage-gate logic, scenarios, and board-ready recommendations.
Indication Expansion
Scan, assess, and sequence indication opportunities with scientific rationale, clinical feasibility, competitive density, IP context, market structure, and valuation logic.
Related reading
How to Produce an Investor-Grade Biotech Valuation Pack
An investor-grade valuation pack starts with an explicit argument about what must be true for the asset to be worth the number.
How to Triage a Portfolio Into Go / Hold / Kill Decisions
Portfolio triage is painful for a reason: it forces the organization to compare stories it would rather evaluate one by one.
From Prompt to Board-Ready Dossier
A board-ready dossier is the visible edge of a research package strong enough to survive second-order questions.